Jennifer Ang Chan MD

Hematologic Oncology

Instructor in Medicine, Dana-Farber Cancer Institute

44 Binney St# DanaBoston, MA 02115
Phone+1 617-632-6315
Fax+1 617-632-5370

Dr. Chan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chan's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2003 - 2028
NH State Medical License 2023 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014-2015, 2017

Clinical Trials

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
COMPLETED
PHASE2
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
COMPLETED
PHASE1, PHASE2
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
COMPLETED
PHASE1

Publications & Presentations

PubMed

Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement.
Udhayvir S Grewal, Po H Ear, Mohamad B Sonbol, Andrew M Bellizzi, Johannes Hofland
Cancer. 2026-08-15
Multiomic analyses delineate human neuroendocrine tumor cell states in relation to normal enteroendocrine cell ontogeny.
Pratik Np Singh, Elsa Hadj Bachir, James R Howe, Andrew M Bellizzi, Paloma Cejas
The Journal of Clinical Investigation. 2026-07-01
Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.
Udhayvir S Grewal, Shagufta Shaheen, David B Zhen, Erik S Mittra, Thorvardur R Halfdanarson
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2026-06-01

Other

Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth
Chan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-optio
UpToDate, Wolters Kluwer Health - 2013-04-15
Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring
Chan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-presentatio
UpToDate, Wolters Kluwer Health - 2012-07-05
Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion
Chan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-systemic-th
UpToDate, Wolters Kluwer Health - 2013-02-05

Press Mentions

FDA Grants Approval for Innovative Dual-Action Therapy Targeting Previously Treated Advanced Neuroendocrine Tumors, Supported by Dana-Farber ResearchMarch 26th, 2025
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber ResearchMarch 26th, 2025
Cabozantinib Improves PFS in Advanced Neuroendocrine Tumors After Prior TreatmentFebruary 13th, 2025